Pharmacological Management of Osteoporosis in Postmenopausal Women
Key Points
Key Points
Consider bisphosphonates as the first line therapeutic choice for postmenopausal women at high risk of fracture.
Reassess fracture risk after patient has been on bisphosphonates for 3-5 years.
Following reassessment, prescribe a “bisphosphonate holiday” for women who are on bisphosphonates and are low-to-moderate risk of fracture.
Consider anabolic therapy (teriparatide or abaloparatide) for women at very high risk of fractures, including those with multiple fractures.
All women undergoing treatment with osteoporosis therapies other than anabolic therapy should consume calcium and vitamin D in their diet or via supplements.
Monitor the BMD of high-risk individuals with a low BMD every 1 to 3 years.
Treatment and Management
...Treatmen...
...W...
...Society (ES) recommends treating postmenopa...
...Bisphosphonat...
...nopausal women at high risk of fractures, ES reco...
...postmenopausal women with osteoporosis who are t...
...De...
...enopausal women with osteoporosis who are at hi...
...postmenopausal women with osteoporosis who...
...nopausal women with osteoporosis taking denosu...
...Teriparatide and Abal...
...: In postmenopausal women with ost...
...2: In postmenopausal women with osteoporosis who...
...Romosozumab...
...postmenopausal women with osteoporosis at very hi...
...postmenopausal women with osteoporosis who have c...
...Selective Estrogen R...
...postmenopausal women with osteoporosis a...
...Menopausal Hormone...
...postmenopausal women at high risk of f...
...opausal women with osteoporosis at h...
...Calcitoni...
...In postmenopausal women at high risk of fract...
...Calcium and Vitami...
...pausal women with low BMD and at high r...
...menopausal women at high risk of fracture wit...
Monitor...
...nopausal women with a low BMD and at high risk o...
...ithm for the Management of Postmenopausal Wome...